Klin Farmakol Farm. 2025;39(4):229-235 | DOI: 10.36290/far.2025.070

A brief overview of pharmacotherapy in palliative medicine - part two

Miroslav Žiaran
Komplexní onkologické centrum Pardubického kraje, Multiscan, s. r. o., Pardubická krajská nemocnice, Pardubice

The second part of the overview of pharmacotherapy in palliative medicine focuses on the treatment of additional symptoms that significantly impair patients' quality of life - dyspnea, nausea and vomiting, constipation, diarrhea, hiccup, and cachexia. The article provides an overview of the etiopathogenesis of these conditions, non-pharmacological interventions, and in particular pharmacological approaches, highlighting their efficacy, safety, and practical application in clinical practice. Emphasis is placed on the need for an individualized approach, appropriate titration of medications, and multidisciplinary collaboration. The text is again intended for physicians of all specialties and aims to promote rational, effective, and safe pharmacotherapy not only in palliative medicine.

Keywords: palliative medicine, pharmacotherapy, dyspnea, nausea, vomiting, constipation, diarrhea, hiccup, cachexia.

Received: September 5, 2025; Revised: December 5, 2025; Accepted: December 7, 2025; Published: December 22, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Žiaran M. A brief overview of pharmacotherapy in palliative medicine - part two. Klin Farmakol Farm. 2025;39(4):229-235. doi: 10.36290/far.2025.070.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hashimoto H, Kanda K. Development and validation of the total dyspnea scale for cancer patients. European Journal of Oncology Nursing, 2019;41:120-125. Go to original source... Go to PubMed...
    2. Hayen A, Heirigstad M, Pattinson K. Understanding dyspnea as a complex individual experience. Maturitas, 2013;76(1): 45-50. Go to original source... Go to PubMed...
    3. Ripamonti C, Fulfaro F, Bruera E. Dyspnoea in patients with advanced cancer: incidence, causes and treatments. Cancer treatment reviews, 1998;24(1):69-80. Go to original source... Go to PubMed...
    4. Simon S, Bausewein C, Schildmann E, et al. Episodic breathlessness in patients with advanced disease: a systematic review. Journal of pain and symptom management. 2013;45(3):561-578. Go to original source... Go to PubMed...
    5. Bausewein C, Booth S, Gysels M, et al. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database of Systematic Reviews.2008;16(2):CD005623. Go to original source... Go to PubMed...
    6. Sundh J, Ekström M. Persistent disabling breathlessness in chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease. 2016;11:2805-2812. Go to original source... Go to PubMed...
    7. O'Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proceedings of the American Thoracic Society. 2007;4(2):145-168. Go to original source... Go to PubMed...
    8. Al-Qadi M, Levarge B, Ford HJ. Epidemiology, pathogenesis, and clinical approach in group 5 pulmonary hypertension. Frontiers in Medicine. 2021;7:616720. Go to original source... Go to PubMed...
    9. Von Leupoldt A, Dahme B. Psychological aspects in the perception of dyspnea in obstructive pulmonary diseases. Respiratory Medicine. 2007;101(3):411-422. Go to original source... Go to PubMed...
    10. Bekelman DB, Havranek EP, Becker DM, et al. Symptoms, depression, and quality of life in patients with heart failure. Journal of cardiac failure. 2007;13(8):643-648. Go to original source... Go to PubMed...
    11. Johnson MJ, Clark AL. The mechanisms of breathlessness in heart failure as the basis of therapy. Current Opinion in Supportive and Palliative Care. 2016;10(1):32-35. Go to original source... Go to PubMed...
    12. Devos E, Jacobson L. Approach to adult patients with acute dyspnea. Emergency Medicine Clinics. 2016;34(1):129-149. Go to original source... Go to PubMed...
    13. Berliner D, Schneider N, Welte T, et al. The differential diagnosis of dyspnea. Deutsches Ärzteblatt International. 2016;113(49):834. Go to original source... Go to PubMed...
    14. Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. The Lancet. 2010;376(9743):784-793. Go to original source... Go to PubMed...
    15. Abernethy AP, Uronis HE, Wheeler, JL, et al. Pharmacological management of breathlessness in advanced disease. Progress in Palliative Care. 2008;16(1):15-20. Go to original source...
    16. Obarzanek L, Wu W, Tutag-Lehr V. Opioid management of dyspnea at end of life: A systematic review. Journal of palliative medicine. 2023;26(5):711-726. Go to original source... Go to PubMed...
    17. Atrux-Tallau N, Naimi Z, Jaudinot E-O. Pharmacokinetics of morphine sulfate orodispersible tablets and bioequivalence with immediate-release oral morphine sulfate formulations in healthy adult subjects under fasting conditions: Single-dose comparative bioavailability studies. Clinical Drug Investigation. 2022;42(12):1101-1112. Go to original source... Go to PubMed...
    18. Simon ST, Köskeroglu P, Bausewein C. Pharmacological therapy of refractory dyspnoea. Schmerz. 2012;26(5):515. Go to original source... Go to PubMed...
    19. Beller EM, Van Driel ML, McGregor L, et al. Palliative pharmacological sedation for terminally ill adults. Cochrane Database of Systematic Reviews. 2015;1. Go to original source... Go to PubMed...
    20. Cherny NI, Fallon M, Kaasa S, et al. Oxford Textbook of Palliative Medicine. 6. vyd. Oxford: Oxford University Press, 2021. ISBN 978-0-19-882132-8.
    21. Davis MP, Hallerberg, G, & Palliative Medicine Study Group of the Multinational Association of Supportive Care in Cancer. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. Journal of pain and symptom management. 2010;39(4):756-767. Go to original source... Go to PubMed...
    22. Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting. ESMO open. 2024;9(2):102195. Go to original source... Go to PubMed...
    23. Glare P, Miller J, Nikolova T, et al. Treating nausea and vomiting in palliative care: a review. Clinical interventions in aging. 2011;6:243-259. Go to original source... Go to PubMed...
    24. Wickham RJ. Nausea and vomiting: a palliative care imperative. Current Oncology Reports. 2020;22(1):1. Go to original source... Go to PubMed...
    25. Stith SS, Li X, Orozco J, et al. The effectiveness of common cannabis products for treatment of nausea. Journal of clinical gastroenterology. 2022;56(4):331-338. Go to original source... Go to PubMed...
    26. Worster B, Hajjar ER, Handley N. Cannabis use in patients with cancer: a clinical review. JCO oncology practice. 2022;18(11):743-749. Go to original source... Go to PubMed...
    27. Graham M, Renaud E, Lucas CJ, et al. Medicinal cannabis guidance and resources for health professionals to inform clinical decision making. Clinical Therapeutics. 2023;45(6): 527-534. Go to original source... Go to PubMed...
    28. Larkin PJ, Sykes NP, Centeno C, et al. The management of constipation in palliative care: clinical practice recommendations. Palliative medicine. 2008;22(7):796-807. Go to original source... Go to PubMed...
    29. Laval G, Arvieux C, Stefani L, et al. Protocol for the treatment of malignant inoperable bowel obstruction: a prospective study of 80 cases at Grenoble University Hospital Center. Journal of pain and symptom management. 2006;31(6):502-512. Go to original source... Go to PubMed...
    30. Jeon YS, Kearney AM, Baker PG. Management of hiccups in palliative care patients. BMJ Supportive & Palliative Care. 2018;8(1):1-6. Go to original source... Go to PubMed...
    31. Steger M, Schneemann M, Fox M. Systemic review: the pathogenesis and pharmacological treatment of hiccups. Alimentary pharmacology & therapeutics. 2015;42(9):1037-1050. Go to original source... Go to PubMed...
    32. Porzio G, Aielli F, Verna L, et al. Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience. Clinical neuropharmacology. 2010;33(4):179-180. Go to original source... Go to PubMed...
    33. Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clinical nutrition. 2021;40(5):2898-2913. Go to original source... Go to PubMed...
    34. Roeland EJ, Bohlke K, Baracos VE, et al. Management of cancer cachexia: ASCO guideline. Journal of Clinical Oncology. 2020;38(21):2438-2453. Go to original source... Go to PubMed...
    35. Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO open. 2021; 6(3):100092. Go to original source... Go to PubMed...
    36. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. The lancet onkology. 2011;12(5):489-495. Go to original source... Go to PubMed...
    37. Chen H, Ishihara M, Kazahari H, et al. Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta-analysis. Cancer Medicine. 2024;13(17):e70166. Go to original source... Go to PubMed...
    38. Hurlow A. Nutrition and hydration in palliative care. British Journal of Hospital Medicine, 2019;80(2):78-85. Go to original source... Go to PubMed...
    39. Cherny NI. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. Journal of pain and symptom management. 2008;36(4):413-423. Go to original source... Go to PubMed...
    40. Tsai J-S, Wu CH, Chiu TY, et al. Symptom patterns of advanced cancer patients in a palliative care unit. Palliative medicine. 2006;20(6):617-622. Go to original source... Go to PubMed...
    41. Clark K, Smith JM, Currow DC. The prevalence of bowel problems reported in a palliative care population. Journal of pain and symptom management. 2012;43(6):993-1000. Go to original source... Go to PubMed...
    42. Kent AJ, Banks MR. Pharmacological management of diarrhea. Gastroenterology Clinics. 2010;39(3):495-507. Go to original source... Go to PubMed...
    43. Vyhláška č. 12/2025 Sb. - Vyhláška, kterou se mění vyhláška č. 236/2015 Sb., o stanovení podmínek pro předepisování, přípravu, distribuci, výdej a používání individuálně připravovaných léčivých přípravků s obsahem konopí pro léčebné použití, ve znění pozdějších předpisů. In: Sbírka zákonů ČR. 2025, částka 12. Dostupné z: https://www.zakonyprolidi.cz/cs/2025-12 [cit. 2025-12-04].

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.